

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Carcinoma

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Status
Recruiting

Trial Runs In
25 Countries

Trial Identifier
NCT06497556 2024-510908-37-00
BO45217

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT06497556 2024-510908-37-00 BO45217
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
